
A treatment arm of up to 3000 participants aged 12-17 years old will be rolled into the North American-based PREVENT-19 trial.

A treatment arm of up to 3000 participants aged 12-17 years old will be rolled into the North American-based PREVENT-19 trial.

Understanding the mechanisms driving inflammation related to IL-6 should be prioritized over rushing to treatment, especially in the era of COVID-19, the study authors said.

Cancer patients are more than twice as likely to acquire hospital-associated Staphylococcus aureus bacteraemia (HA-SAB) and Clostridioides difficile infection (HA-CDI) than others, a new study from Australia found.

The multidisciplinary, retrospective analysis showed that long-term outcomes of ECMO patients did not vary from that of others.

The US will initiate travel restrictions beginning May 4th, due to the surging COVID-19 case load in India.

The report details what symptoms vaccinated people should look out for, as well as treatment details for healthcare professionals.

While a slightly higher rate of morbidity was observed, a small percentage of babies presented with COVID-19 after birth.

With its mRNA COVID-19 vaccine authorized, the company is employing the technology to take aim at a variety of pathogens.

A new study assessed the life expectancy gains for those adults with HIV and being treated with antiretroviral therapy living in Latin America and the Caribbean.

A prolonged infection can allow a virus to mutate more often, potentially letting more transmissible variants to emerge.

Pre-existing conditions were found to increase the risk of COVID-19 related death in those with diabetes.

The confusion and uncertainty surrounding the need for a second dose among the public shows the need for better guidance from the medical community.

Patients who received the inhaled glucocorticoid budesonide in the first several days of COVID-19 symptoms were much less likely to require hospital care.

The new report highlights the broad disparities in HIV health among different populations, with Black transgender women facing the highest rates of HIV infection.

This is our inaugural segment for our new video series, 1 Big Question, where we ask the medical community a question about a significant infectious disease topic and get feedback from them.

The most common symptoms were headache, fatigue and soreness at the injection site.

The proportion of cases with CDI in perforated appendicitis was found to be greater in comparison to the non-perforated cases.

A pair of recent studies suggest that the ability of people with blood cancers lymphocytic leukemia and multiple myeloma to produce antibodies in response to COVID-19 vaccines is impaired.

Surveys suggest most students plan to get the shots anyway.

The discovery of these nanobodies may help to create treatments that can protect against COVID-19, as well as future variants of the virus.

Individuals who are fully vaccinated can shed their masks when exercising outdoors and gathering in small groups.

Exposure to a segment of the viral spike protein induced COVID-19 like symptoms and caused lung damage similar to those with the disease.

Even in mild cases, symptoms of COVID-19 can linger for at least 8 months, according to new research.

CDC report highlights disparities among “racial, ethnic, gender, and sexual” minorities.

Treatment with rifampin shows it can increase the chances for recurrent Clostridium difficile (C diff) infection according to investigators in Mexico.

The Biden Administration plans to donate the AstraZeneca vaccines globally upon clearance of safety reviews.

Thailand steps up travel restrictions among a rapidly spreading third wave of the disease.

There have been sporadic cases Hemophagocytic Lymphohistiocytosis, associated with Cytomegalovirus Infection infection, suggesting that CMV may cause clinically significant disease beyond mononucleosis in immunocompetent individuals.

The discovery of C diff’s ability to harness heme to shield itself from the body’s immune responses hopefully brings a new dimension to the fight against the damaging pathogen.

Nursing home residents who had recovered from COVID-19 showed robust antibody levels against the SARS-CoV-2 spike protein after 1 dose of messenger RNA (mRNA) vaccine, a study in France showed.